Pharmaceuticals

Clearside Biomedical

Clearside Biomedical released FY2025 Q3 earnings on November 14 (EST), actual revenue USD 201 K (forecast USD 88 K), actual EPS USD -1.141 (forecast USD -0.525)

Clearside Biomedical released FY2025 9 Months Earnings on November 14, 2025 (EST) with actual revenue of USD 3.023 M and actual EPS of USD -3.6106

Clearside Biomedical released FY2025 Semi-Annual earnings on August 8, 2025 (EST) with actual revenue of USD 2.822 M and EPS of USD -0.1643

Clearside Biomedical released FY2025 Q2 earnings on August 8 (EST), actual revenue USD 492 K (forecast USD 169.86 K), actual EPS USD -0.8661 (forecast USD -1.5214)

Clearside Biomedical Exploring Strategic Options

Clearside to Demonstrate Retinal Disease Treatment Technology at Clinical Trials Summit

Clearside Biomedical Annual Meeting Approves Multiple Proposals

Clearside Biomedical to Participate in Stifel 2025 Virtual Ophthalmology Forum

JPMorgan Maintains Outperform Rating on Clearside Biomedical

Needham lowers CLEARSIDE Biomedical's target price from $4 to $3

Clearside Biomedical released FY2025 Q1 earnings on May 14 After-Market EST, actual revenue USD 2.33 M (forecast USD 197.83 K), actual EPS USD -1.6035 (forecast USD -1.6285)

Clearside Biomedical Reports Reduced Net Loss in Q1 2025 Earnings

Clearside Biomedical Presents CLS-AX Project at ARVO Conference

Clearside Biomedical to Release FY2025 Q1 Earnings on May 14 After-Market EST, Forecast Revenue USD 197.83K, EPS USD -0.1085

Clearside Biomedical Inc Reports Quarterly Loss of 11 Cents Per Share

Needham & Company LLC Reaffirms Buy Rating for Clearside Biomedical with Target Price of $4.00

Needham Adjusts Clearside Biomedical (CLSD.US) Rating from Buy to Buy, Target Price from $6.00 to $4.00

Clearside Biomedical released FY2024 earnings on March 27 After-Market EST, actual revenue USD 1.664 M (forecast USD 1.676 M), actual EPS USD -6.9817 (forecast USD -7.0071)

Clearside Biomedical released FY2024 Q4 earnings on March 27 After-Market (EST), actual revenue USD 306K (forecast USD 294.43K), actual EPS USD -1.4448 (forecast USD -1.4571)

Clearside Biomedical Inc Reports Quarterly Financial Results, Loss Widens, Revenue Declines 95.2%

AdvisorShares MSOS 2x Daily ETF

cbdMD

Tryhard

Roundhill Cannabis ETF

Neo-Concept

Amplify Seymour Cannabis ETF

AdvisorShares Pure US Cannabis ETF

Canopy Growth

RYTHM

Tilray Brands

Ticker Change

代码变更

From 2025.12.01 (EST) changed to CLSDQ

Eli Lilly

ROCHE HOLDINGS AG

Roche

Astrazeneca

NOVARTIS AG

Novo Nordisk AS

Chugai Pharmaceutical

UCB S.A.

Daiichi Sankyo

Otsuka Pharmaceutical

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap